February is the “sumup” month for the NEVERMIND project.
As for every work, every project, every team, sometimes you have to stop, summarize results, look at pitfalls, solve problems to keep on going.
For the NEVERMIND project, the Consortium meetings occur every 6 months (with extra meeting in small groups more frequently, of course), but once a year we put together the whole work done, summarize the achievements and also eventual difficulties to report to our sponsor how the project is going.
And here we briefly and schemaatically update you about 2021 activities, looking at the main goals of the project:
-
We have successfully developed new strategies to functionalize the nanoliposome
-
We have loaded them with drugs specifically directive towards glioblastoma (GBM) cells and Alzheimer’s disease (AD) lesions
-
Work is still in progress, but main characterization test gave a positive feedback about the reproducibility of the synthesis and about the preserved binding kinetic of the surface receptors that direct the nanodrugs to the brain and of the encapsulated drugs, once released by the liposomes
-
Preliminary data on nanovector efficacy and biocompatibility as well as tests on BBB crossing have provided extremely good results! We are ready to start more complex analysis and in vivo tests that will be the crucial experimental part of the third year of the project
We have presented some of the results at national and international congresses and the first two publications have been released.
Antoniou, A.I; Giofrè, S.; Seneci, P.; Passarella, D.; Pellegrino, S. Stimulus-responsive liposomes for biomedical applications. Drug Discovery Today 26 (2021), 1794-1824.
Taiarol L; Formicola B; Fagioli S; Sierri G.; D’Aloia A.; Kravicz M.; Renda A.; Viale F.; Dal Magro R.; Ceriani M.; Re F. “The 3.0 Cell Communication: New Insights in the Usefulness of Tunneling Nanotubes for Glioblastoma Treatment” Cancers (Basel) 2021 Aug 8;13(16):4001. doi: 10.3390/cancers13164001
